[Federal Register Volume 70, Number 72 (Friday, April 15, 2005)]
[Notices]
[Pages 19964-19965]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 05-7543]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Prospective Grant of Exclusive License: Methods for Treating 
Inflammatory Bowel Disease Using Cholera Toxin B Subunit

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 
CFR 404.7(a)(1)(i), that the National Institutes of Health, Department 
of Health and Human Services, is contemplating the grant of an 
exclusive patent license to practice the inventions embodied in U.S. 
Patent Application 10/129,907, filed May 10, 2002 [DHHS Ref. E-263-
1999/0-US-03], entitled ``Methods for treating inflammatory bowel 
disease using cholera toxin B subunit,'' to SBL Vaccin AB, which is 
located in Stockholm, Sweden. The patent rights in these inventions 
have

[[Page 19965]]

been assigned to the United States of America.
    The prospective exclusive license territory may be worldwide and 
the field of use may be limited to the use of cholera toxin B as a 
therapeutic treatment of inflammatory bowel disease, specifically 
Crohn's disease.

DATES: Only written comments and/or applications for a license which 
are received by the NIH Office of Technology Transfer on or before June 
14, 2005, will be considered.

ADDRESSES: Requests for copies of the patent application, inquiries, 
comments, and other materials relating to the contemplated exclusive 
license should be directed to: Michelle A. Booden, Ph.D., Technology 
Licensing Specialist, Office of Technology Transfer, National 
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, 
MD 20852-3804; telephone: (301) 451-7337; Facsimile: (301) 402-0220; e-
mail: [email protected].

SUPPLEMENTARY INFORMATION: The technology describes a method of 
treating or preventing inflammatory bowel disease by administrating 
cholera toxin B subunit (CT-B). Specifically, the patent application 
discloses administrating CT-B as a method for treating and preventing 
Crohn's disease (CD) and Ulcerative Colitis (UC) as well as a method 
for treating and preventing inflammation and/or autoimmune disorders 
mediated by increased interferon gamma (INF-[gamma]) and or interleukin 
12 (IL-12).
    The prospective exclusive license will be royalty bearing and will 
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. 
The prospective exclusive license may be granted unless within sixty 
(60) days from the date of this published notice, the NIH receives 
written evidence and argument that establishes that the grant of the 
license would not be consistent with the requirements of 35 U.S.C. 209 
and 37 CFR 404.7.
    Applications for a license in the field of use filed in response to 
this notice will be treated as objections to the grant of the 
contemplated exclusive license. Comments and objections submitted to 
this notice will not be made available for public inspection and, to 
the extent permitted by law, will not be released under the Freedom of 
Information Act, 5 U.S.C. 552.

    Dated: April 6, 2005.
Steven M. Ferguson,
Director, Division of Technology Development and Transfer, Office of 
Technology Transfer, National Institutes of Health.
[FR Doc. 05-7543 Filed 4-14-05; 8:45 am]
BILLING CODE 4140-01-P